Indication

Spinal muscular atrophy

Spinal muscular atrophy is a rare, hereditary neuromuscular disorder primarily caused by biallelic mutations or deletions in the *SMN1* gene, leading to a deficiency of survival motor neuron protein. Read more about Spinal muscular atrophy

5 drugs 5 manufacturers

Advertisement

Drugs that treat it

Common Spinal muscular atrophy therapies.

Showing 1–5 of 5 drugs

EVRYSDI (risdiplam)

GENETIC DISORDER THERAPY - SMN PROTEIN DEFICIENCY TREATMENT·SPINAL MUSCULAR ATROPHY
GENENTECH
Filter & compare in the drug finder →Opens the drug finder with Spinal muscular atrophy preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Spinal muscular atrophy.

Spinal muscular atrophy is a rare, hereditary neuromuscular disorder primarily caused by biallelic mutations or deletions in the *SMN1* gene, leading to a deficiency of survival motor neuron protein.

This deficit results in the progressive degeneration and loss of lower motor neurons within the anterior horn of the spinal cord and lower brainstem.

Pathophysiologically, the disease manifests as symmetric, progressive muscle weakness and wasting that predominantly impacts proximal limb muscles, axial musculature, and respiratory muscles.

Clinical severity spans a broad continuum—from severe infantile-onset weakness with early respiratory failure to milder juvenile or adult-onset forms that impair ambulation.

Personalize your experience

Follow Spinal muscular atrophy and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it